Related Experiment Video
Updated: Jan 26, 2026

Direct Drug Delivery to Kidney via the Renal Artery
Published on: April 17, 2021
Severe Arterial Hypertension from Cullin 3 Mutations Is Caused by Both Renal and Vascular Effects
Waed Abdel Khalek1,2, Chloé Rafael1,2,3,4,5, Irmine Loisel-Ferreira1,2
1Institut National de la Santé et de la Recherche Médicale U970, Paris Cardiovascular Research Center, Paris, France.
Insights
Mutations in Cullin 3 (CUL3) cause severe familial hyperkalemic hypertension (FHHt) by impacting both kidney and blood vessel function. This study reveals CUL3 mutations activate RhoA, contributing to vascular dysfunction in FHHt.
Area of Science:
- Genetics and Molecular Biology
- Cardiovascular Research
- Nephrology
Background:
- Familial hyperkalemic hypertension (FHHt) is a rare genetic disorder.
- Mutations in WNK1, WNK4, KLHL3, or CUL3 genes cause FHHt.
- CUL3 mutations, specifically exon 9 skipping, lead to a more severe FHHt phenotype.
Purpose of the Study:
- To investigate the mechanisms by which CUL3 mutations cause severe hypertension.
- To compare the effects of ubiquitous versus vascular smooth muscle-specific expression of mutant Cul3 (Cul3∆9).
- To elucidate the roles of renal and vascular factors in CUL3-associated hypertension.
Main Methods:
- Generated and compared two mouse models: ubiquitous (pgk-Cul3∆9) and vascular smooth muscle-specific (SM22-Cul3∆9) Cul3∆9 expression.
- Performed pharmacologic studies on isolated aortas.
- Created HEK293 cell lines overexpressing wild-type or mutant Cul3.
- Analyzed blood pressure, electrolyte levels, gene expression, and protein abundance.
Main Results:
- pgk-Cul3∆9 mice exhibited hypertension, hyperkalemia, hyperchloremia, and low renin.
- SM22-Cul3∆9 mice showed increased blood pressure without significant renal transport changes.
- Both models displayed altered aortic reactivity and amlodipine sensitivity.
- Aortas from SM22-Cul3∆9 mice showed increased RhoA expression, linked to decreased ubiquitination in Cul3∆9 cells.
Conclusions:
- CUL3 mutations induce severe hypertension through combined renal and vascular dysfunction.
- Vascular dysfunction in CUL3-associated hypertension involves RhoA activation.
- Understanding these mechanisms may inform therapeutic strategies for FHHt.
Background:
Mutations in four genes, WNK lysine deficient protein kinase 1 and 4 (WNK1 and WNK4), kelch like family member 3 (KLHL3), or Cullin 3 (CUL3), can result in familial hyperkalemic hypertension (FHHt), a rare Mendelian form of human arterial hypertension. Although all mutations result in an increased abundance of WNK1 or WNK4, all FHHt-causing CUL3 mutations, resulting in the skipping of exon 9, lead to a more severe phenotype.
Methods:
We created and compared two mouse models, one expressing the mutant Cul3 protein ubiquitously (pgk-Cul3∆9) and the other specifically in vascular smooth muscle cells (SM22-Cul3∆9). We conducted pharmacologic investigations on isolated aortas and generated stable and inducible HEK293 cell lines that overexpress the wild-type Cul3 or mutant Cul3 (Cul3∆9) protein.
Results:
As expected, pgk-Cul3∆9 mice showed marked hypertension with significant hyperkalemia, hyperchloremia and low renin. BP increased significantly in SM22-Cul3∆9 mice, independent of any measurable effect on renal transport. Only pgk-Cul3∆9 mice displayed increased expression of the sodium chloride cotransporter and phosphorylation by the WNK-SPAK kinases. Both models showed altered reactivity of isolated aortas to phenylephrine and acetylcholine, as well as marked acute BP sensitivity to the calcium channel blocker amlodipine. Aortas from SM22-Cul3∆9 mice showed increased expression of RhoA, a key molecule involved in regulation of vascular tone, compared with aortas from control mice. We also observed increased RhoA abundance and t1/2 in Cul3∆9-expressing cells, caused by decreased ubiquitination.
Conclusions:
Mutations in Cul3 cause severe hypertension by affecting both renal and vascular function, the latter being associated with activation of RhoA.
More Related Videos
Related Concept Videos
Mutations
Mutations
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Viral Mutations

